Compare Ascendis Pharma A/S (ASND) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Ascendis Pharma A/S trades at $246.23 (market cap $16.71B), while YieldMax NVDA Option Income Strategy ETF trades at $13.04. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | NVDY | |
|---|---|---|
Market Cap | $16.71B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $17.21 |
52-Week Low | $189.74 | $11.58 |
Enterprise Value | $17.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, up 0.35% on the day, with a bullish technical outlook and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $3.29 versus $1.71 expected, driven by robust product revenue growth of 105% year-over-year. The company shows improving financials, with net cash flow turning positive in 2025 and revenue projected to reach $866 million in 2026. Institutional sentiment is highly positive, with 92% of analysts rating the stock a buy.
The outlook for ASND is optimistic, supported by accelerating revenue growth, multiple product launches, and a path to profitability. Key risks include high debt levels, ongoing net losses, and competitive pressures in rare disease markets. The consensus price target of $309.75 implies significant upside, but investors should monitor execution on profitability goals and regulatory developments.
NVDY, trading at $13.06 with a 2.51% daily gain, shows bullish technical signals from moving averages but a neutral RSI. The ETF generates weekly dividend income, with recent payouts ranging from $0.09 to $0.14, though news highlights concerns about sacrificing NVIDIA's upside potential for yield.
The outlook balances high income distribution against capped growth from option strategies. Risks include underperformance versus NVIDIA stock and fee impacts, while the current technical trend supports near-term stability but requires monitoring for overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
